Literature DB >> 21126685

Bevacizumab and breast cancer: the E2100 outlier.

Tito Fojo, Julia Wilkerson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21126685     DOI： 10.1016/S1470-2045(10)70259-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  5 in total

Review 1.  Benefit-risk assessment of bevacizumab in the treatment of breast cancer.

Authors:  Rodrigo Dienstmann; Felipe Ades; Kamal S Saini; Otto Metzger-Filho
Journal:  Drug Saf       Date:  2012-01-01       Impact factor: 5.606

2.  5-Fluorouracil vs avastin as adjunct to conjunctival autograft in the surgical treatment of pterygium.

Authors:  C O Bekibele; T F Sarimiye; A Ogundipe; S Olaniyan
Journal:  Eye (Lond)       Date:  2016-03-18       Impact factor: 3.775

3.  Targeting angiogenesis in metastatic breast cancer.

Authors:  Sangeetha Reddy; Michael Raffin; Virginia Kaklamani
Journal:  Oncologist       Date:  2012-07-27

4.  Targeting the tumor microenvironment: focus on angiogenesis.

Authors:  Fengjuan Fan; Alexander Schimming; Dirk Jaeger; Klaus Podar
Journal:  J Oncol       Date:  2011-08-24       Impact factor: 4.375

5.  Subconjunctival bevacizumab for primary pterygium excision; a randomized clinical trial.

Authors:  Mohammad-Reza Razeghinejad; Mohammad Banifatemi
Journal:  J Ophthalmic Vis Res       Date:  2014-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.